| scholarly article | Q13442814 |
| P50 | author | Cyril Šálek | Q41724612 |
| Iuri Marinov | Q41724615 | ||
| P2093 | author name string | Michael Doubek | |
| Bohumír Procházka | |||
| Petr Cetkovský | |||
| Iuri Marinov | |||
| Jiří Mayer | |||
| Eva Froňková | |||
| Cyril Šálek | |||
| František Folber | |||
| Czech Leukemia Study Group - for Life | |||
| P2860 | cites work | Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia | Q27852997 |
| Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802. | Q34455093 | ||
| Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia | Q35542516 | ||
| Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study) | Q36616666 | ||
| UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia | Q37564762 | ||
| Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. | Q37662200 | ||
| Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). | Q38384261 | ||
| Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. | Q42974471 | ||
| Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. | Q43266780 | ||
| Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571). | Q44189698 | ||
| Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study. | Q44670719 | ||
| Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. | Q46174384 | ||
| Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. | Q52914164 | ||
| Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. | Q54639337 | ||
| Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) | Q58414406 | ||
| P433 | issue | 3 | |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 276-284 | |
| P577 | publication date | 2015-05-21 | |
| P1433 | published in | European Journal of Haematology | Q15765799 |
| P1476 | title | Early MRD response as a prognostic factor in adult patients with acute lymphoblastic leukemia | |
| P478 | volume | 96 |
| Q39192991 | Acute lymphoblastic leukemia in adolescents and young adults |
| Q47955491 | An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia |
| Q50248991 | Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia |
| Q92860019 | Minimal Residual Disease in Acute Lymphoblastic Leukemia: Technical and Clinical Advances |
| Q89777621 | Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation |
| Q49989331 | Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. |
| Q51343198 | Prognostic significance of IKZF1 deletion in adult B cell acute lymphoblastic leukemia: a meta-analysis. |
| Q90215009 | Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward |
Search more.